CCM
EPZM

Consonance Capital Management’s Epizyme, Inc EPZM Stock Holding History

Consonance Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,304,918
Closed -$51.3M – 40
2020
Q1 		$51.3M Sell
3,304,918
-1,001,657
-23% -$21.5M 3.82% 10
2019
Q4 		$106M Buy
4,306,575
+331,521
+8% +$4.92M 6.47% 4
2019
Q3 		$41M Sell
3,975,054
-785,005
-16% -$9.9M 4.06% 11
2019
Q2 		$59.7M Buy
4,760,059
+1,281,798
+37% +$16.5M 4.23% 8
2019
Q1 		$43.1M Buy
+3,478,261
New +$38.9M 2.72% 14

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Consonance Capital Management's EPZM Position: Q2 2020 in Review

Consonance Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 3,304,918 shares — an estimated $51.3M sold.

Consonance Capital Management first reported a position in EPZM in Q1 2019 and held it in 5 quarters. The position peaked at $106M in Q4 2019. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

  • Consonance Capital Management reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 3,304,918 Epizyme, Inc shares in Q2 2020, an estimated $51.3M.
  • Consonance Capital Management first reported a position in Epizyme, Inc in Q1 2019 and held it in 5 quarters.
  • Consonance Capital Management's Epizyme, Inc position peaked at $106M in Q4 2019.
  • 160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.